A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
Sponsor: Astex Pharmaceuticals, Inc.
A PHASE2 clinical study on Myeloproliferative Neoplasms, this trial is completed. The trial is conducted by Astex Pharmaceuticals, Inc. and has accumulated 12 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE2
-
May 2022 — Jun 2022 [monthly]
Completed PHASE2
-
Sep 2021 — May 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
May 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2020 — May 2020 [monthly]
Recruiting PHASE2
-
Apr 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE2
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astex Pharmaceuticals, Inc.
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .